Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239752885> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4239752885 endingPage "39" @default.
- W4239752885 startingPage "39" @default.
- W4239752885 abstract "<h3>Background</h3> Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against weak self-antigens expressed on cancer cells. For instance, a peptide/CpG-based cancer vaccine has been evaluated in several clinical trials and was shown in pre-clinical studies to favor the expansion of effector T versus Tregs cells, resulting in a potent antitumor activity, as compared to other TLR ligands. Alternatively, the adjuvant activity of CD1d-restricted invariant NKT cells (iNKT) on the innate and adaptive immunity is well demonstrated, and several CD1d glycolipid ligands are under pre-clinical and clinical evaluation. Importantly, additive or even synergistic effects have been shown upon combined CD1d/NKT agonists and TLR ligands. The aim of the present study is to combine the activation and tumor targeting of activated iNKT, NK and T cells. <h3>Methods</h3> Activation and tumor targeting of iNKT cells via recombinant α-galactosylceramide (αGC)-loaded CD1d-anti-HER2 fusion protein (CD1d-antitumor) is combined or not with OVA peptide/CpG vaccine. Circulating and intratumoral NK and H-2Kb/OVA-specific CD8 responses are monitored, as well as the state of activation of dendritic cells (DC) with regard to activation markers and IL-12 secretion. The resulting antitumor therapy is tested against established tumor grafts of B16 melanoma cells expressing human HER2 and ovalbumin. <h3>Results</h3> The combined CD1d/iNKT antitumor therapy and CpG/peptide-based immunization leads to optimized expansion of NK and OVA-specific CD8 T cells (CTLs), likely resulting from the maturation of highly pro-inflammatory DCs as seen by a synergistic increase in serum IL-12. The enhanced innate and adaptive immune responses result in higher tumor inhibition that correlates with increased numbers of OVA-specific CTLs at the tumor site. Antibody-mediated depletion experiments further demonstrate that in this context, CTLs rather than NK cells are essential for the enhanced tumor inhibition. <h3>Conclusions</h3> Altogether, our study in mice demonstrates that αGC/CD1d-antitumor fusion protein greatly increases the efficacy of a therapeutic CpG-based cancer vaccine, first as an adjuvant during T cell priming and second, as a therapeutic agent to redirect immune responses to the tumor site." @default.
- W4239752885 created "2022-05-12" @default.
- W4239752885 creator A5004102058 @default.
- W4239752885 creator A5032787363 @default.
- W4239752885 creator A5070783372 @default.
- W4239752885 creator A5071971878 @default.
- W4239752885 creator A5079396804 @default.
- W4239752885 creator A5087604368 @default.
- W4239752885 date "2014-01-01" @default.
- W4239752885 modified "2023-09-26" @default.
- W4239752885 title "iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine" @default.
- W4239752885 doi "https://doi.org/10.1186/preaccept-1215021284136925" @default.
- W4239752885 hasPublicationYear "2014" @default.
- W4239752885 type Work @default.
- W4239752885 citedByCount "0" @default.
- W4239752885 crossrefType "journal-article" @default.
- W4239752885 hasAuthorship W4239752885A5004102058 @default.
- W4239752885 hasAuthorship W4239752885A5032787363 @default.
- W4239752885 hasAuthorship W4239752885A5070783372 @default.
- W4239752885 hasAuthorship W4239752885A5071971878 @default.
- W4239752885 hasAuthorship W4239752885A5079396804 @default.
- W4239752885 hasAuthorship W4239752885A5087604368 @default.
- W4239752885 hasBestOaLocation W42397528851 @default.
- W4239752885 hasConcept C104317684 @default.
- W4239752885 hasConcept C139563560 @default.
- W4239752885 hasConcept C140173407 @default.
- W4239752885 hasConcept C147483822 @default.
- W4239752885 hasConcept C150194340 @default.
- W4239752885 hasConcept C167672396 @default.
- W4239752885 hasConcept C190727270 @default.
- W4239752885 hasConcept C193419808 @default.
- W4239752885 hasConcept C203014093 @default.
- W4239752885 hasConcept C2777701055 @default.
- W4239752885 hasConcept C2777863537 @default.
- W4239752885 hasConcept C2778378633 @default.
- W4239752885 hasConcept C2778607024 @default.
- W4239752885 hasConcept C2780674031 @default.
- W4239752885 hasConcept C502942594 @default.
- W4239752885 hasConcept C55493867 @default.
- W4239752885 hasConcept C71924100 @default.
- W4239752885 hasConcept C86803240 @default.
- W4239752885 hasConcept C8891405 @default.
- W4239752885 hasConceptScore W4239752885C104317684 @default.
- W4239752885 hasConceptScore W4239752885C139563560 @default.
- W4239752885 hasConceptScore W4239752885C140173407 @default.
- W4239752885 hasConceptScore W4239752885C147483822 @default.
- W4239752885 hasConceptScore W4239752885C150194340 @default.
- W4239752885 hasConceptScore W4239752885C167672396 @default.
- W4239752885 hasConceptScore W4239752885C190727270 @default.
- W4239752885 hasConceptScore W4239752885C193419808 @default.
- W4239752885 hasConceptScore W4239752885C203014093 @default.
- W4239752885 hasConceptScore W4239752885C2777701055 @default.
- W4239752885 hasConceptScore W4239752885C2777863537 @default.
- W4239752885 hasConceptScore W4239752885C2778378633 @default.
- W4239752885 hasConceptScore W4239752885C2778607024 @default.
- W4239752885 hasConceptScore W4239752885C2780674031 @default.
- W4239752885 hasConceptScore W4239752885C502942594 @default.
- W4239752885 hasConceptScore W4239752885C55493867 @default.
- W4239752885 hasConceptScore W4239752885C71924100 @default.
- W4239752885 hasConceptScore W4239752885C86803240 @default.
- W4239752885 hasConceptScore W4239752885C8891405 @default.
- W4239752885 hasIssue "1" @default.
- W4239752885 hasLocation W42397528851 @default.
- W4239752885 hasLocation W42397528852 @default.
- W4239752885 hasOpenAccess W4239752885 @default.
- W4239752885 hasPrimaryLocation W42397528851 @default.
- W4239752885 hasRelatedWork W1973286952 @default.
- W4239752885 hasRelatedWork W2090324576 @default.
- W4239752885 hasRelatedWork W2095967285 @default.
- W4239752885 hasRelatedWork W2111140175 @default.
- W4239752885 hasRelatedWork W2275222446 @default.
- W4239752885 hasRelatedWork W2289160872 @default.
- W4239752885 hasRelatedWork W2418534979 @default.
- W4239752885 hasRelatedWork W2921443070 @default.
- W4239752885 hasRelatedWork W4239752885 @default.
- W4239752885 hasRelatedWork W2178289793 @default.
- W4239752885 hasVolume "2" @default.
- W4239752885 isParatext "false" @default.
- W4239752885 isRetracted "false" @default.
- W4239752885 workType "article" @default.